ClinicalTrials.Veeva

Menu

Efficacy and Safety of Jianpi Qinghua Granules in Patients With Nonerosive Reflux Disease

X

Xiyuan Hospital of China Academy of Chinese Medical Sciences

Status and phase

Unknown
Early Phase 1

Conditions

Nonerosive Reflux Disease

Treatments

Drug: Jianpi Qinghua placebo granules
Drug: Jianpi Qinghua granules

Study type

Interventional

Funder types

Other

Identifiers

NCT04324138
2019YFC1709602-

Details and patient eligibility

About

Nonerosive reflux disease (NERD) is a common refractory gastrointestinal disease. Proton pump inhibitors (PPIs), the first choice drug, have the following problems in clinical use: about 50 % of patients have no response to PPIs; the efficacy of simple acid suppression is poor; long-term use of PPIs can lead to indigestion, gastric polyps, atrophic gastritis, intestinal dysbacteriosis. Spleen Deficiency and Damp-heat Syndrome is one of the common clinical syndrome of NERD.TCM syndrome differentiation and treatment has the advantages of overall regulation and individualized treatment, but lack of high-level evidence. The purpose of this study is to evaluate the efficacy and safety of Jianpi Qinghua Granules for treating NERD with spleen deficiency and damp heat syndrome.

Full description

Nonerosive reflux disease (NERD), representing about 70% of gastroesophageal reflux disease, is a common refractory gastrointestinal disease. Proton pump inhibitors (PPIs), the first choice drug, have the following problems in clinical use: about 50 % of patients have no response to PPIs; the efficacy of simple acid suppression is poor; long-term use of PPIs can lead to indigestion, gastric polyps, atrophic gastritis, intestinal dysbacteriosis. Spleen Deficiency and Damp-heat Syndrome is one of the common clinical syndrome of NERD.TCM syndrome differentiation and treatment has the advantages of overall regulation and individualized treatment, but lack of high-level evidence. NERD is the result of multifactorial pathogenicity. The reflux symptoms not only related to acid reflux, but also related to alkali, gas, mixed reflux, etc. The theory of Tongjiang put forward by Academician Dong Jianhua.Under the guidance of Academician Dong Jianhua, the research team create a prescription Jianpi Qinghua granule for treating NERD with spleen deficiency and damp-heat syndrome. The purpose of this study is to evaluate the efficacy and safety of Jianpi Qinghua Granules for treating NERD with spleen deficiency and damp heat syndrome based on a a multicenter,randomized, double-blind, placebo-controlled clinical trial.

On the basis of previous work, the project plans to establish sub centers in 3 Chinese hospitals, including78 patients with NERD and spleen deficiency and damp-heat syndrome. The therapeutic effects were evaluated from the following aspects: the VAS score of reflow and heartburn, the rate of discontinuation of antacids, the rate of recurrence of NERD symptoms, the score of TCM syndromes and the improvement of gastrointestinal function.

Enrollment

78 estimated patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Subjects diagnosed with non-erosive reflux disease
  2. Subjects who have a medical history of PPI with poor therapeutic effect
  3. Subjects aged between 18 and 70 years
  4. Subjects diagnosed with spleen deficiency damp-heat syndrome of traditional Chinese medicine
  5. Subjects who voluntarily signed written informed consent form

Exclusion criteria

  1. Subjects who have active peptic ulcer, gastrointestinal hemorrhage, severe dysplasia of gastric mucosa or suspected malignant change, achalasia or postoperative achalasia
  2. Subjects who have organic diseases of the digestive system (such as acute and chronic pancreatitis, cirrhosis, etc.), or systemic diseases that affect the gastrointestinal motility, such as hyperthyroidism, diabetes mellitus over 10 years, chronic renal insufficiency, spirit (the score of SAS and SDS shows severe anxiety or depression), nervous system diseases, etc
  3. Subjects who have severe organ diseases such as heart, liver and kidney (such as ALT, AST more than 2 times of normal value), hematopoietic system diseases and tumors
  4. Pregnant or lactating women
  5. Subjects who have a history of nervous system disease and mental disease
  6. Subjects who have a history of allergies to all the test drugs
  7. Subjects who are participating in other clinical trials or have participated in other clinical trials within 4 weeks

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Triple Blind

78 participants in 2 patient groups

Experimental group
Experimental group
Description:
Jianpi Qinghua granules, 3 times a day and 1 hour after a meal
Treatment:
Drug: Jianpi Qinghua granules
Control group
Sham Comparator group
Description:
Jianpi Qinghua placebo granules(inclued 5% of experimental drug),3 times a day and 1 hour after a meal
Treatment:
Drug: Jianpi Qinghua placebo granules

Trial contacts and locations

1

Loading...

Central trial contact

beihua zhang, M.D

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems